Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
7.75
-0.12 (-1.52%)
At close: May 12, 2025, 4:00 PM
7.77
+0.02 (0.26%)
After-hours: May 12, 2025, 7:44 PM EDT
Zevra Therapeutics Revenue
In the year 2024, Zevra Therapeutics had annual revenue of $23.61M, down -14.02%. Zevra Therapeutics had revenue of $12.04M in the quarter ending December 31, 2024, a decrease of -6.79%.
Revenue (ttm)
$23.61M
Revenue Growth
-14.02%
P/S Ratio
15.18
Revenue / Employee
$400,203
Employees
59
Market Cap
423.77M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 23.61M | -3.85M | -14.02% |
Dec 31, 2023 | 27.46M | 17.30M | 170.26% |
Dec 31, 2022 | 10.16M | -18.49M | -64.53% |
Dec 31, 2021 | 28.65M | 15.36M | 115.61% |
Dec 31, 2020 | 13.29M | 449.00K | 3.50% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ZVRA News
- 6 days ago - Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call - GlobeNewsWire
- 25 days ago - Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism - GlobeNewsWire
- 5 weeks ago - Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million - GlobeNewsWire
- 6 weeks ago - Zevra Therapeutics Files Preliminary Proxy - GlobeNewsWire
- 2 months ago - Zevra Therapeutics, Inc. (ZVRA) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Zevra Reports Full Year 2024 and Fourth Quarter Financial Results - GlobeNewsWire
- 2 months ago - Zevra Launches New Disease State Awareness Campaign, ‘Learn NPC, Read Between the Signs,' to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C - GlobeNewsWire
- 2 months ago - Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million - GlobeNewsWire